Comparative evaluation of the concentration-dependent effect of proton-pump inhibitor in association with calcium hydroxide and chlorhexidine on Enterococcus faecalis: An in vitro study

R Anija¹, Chandana Kalita¹, A C Bhuyan¹, M D Iftikar Hussain², Anindita Saikia¹, Lima Das¹
¹Department of Conservative Dentistry and Endodontics, Regional Dental College, ²Department of Animal Biotechnology, College of Veterinary Science, Guwahati, Assam, India

Abstract  
Background: Enterococcus faecalis is the most persistent organism in the root canal which resists most of the intracanal medicaments. There is always a constant attempt to eliminate this endodontic pathogen from the root canal system.  
Aim: The aim of this study was to evaluate the efficacy of the association of different concentrations of proton-pump inhibitor (PPI) (Lansoprazole) with calcium hydroxide (CH) and chlorhexidine (CHX) against E. faecalis using a broth dilution method.  
Materials and Methods: E. faecalis was inoculated into brain–heart infusion broth at 37°C for 5 h. The master broth was then treated with CH (Group 1); CH + 2% CHX (Group 2); CH + PPI 6.25 µg/ml (Group 3A); CH + PPI 25 µg/ml (Group 3B); 2% CHX + PPI 6.25 µg/ml (Group 4A); 2% CHX + PPI 25 µg/ml (Group 4B); CH + 2% CHX + PPI 6.25 µg/ml (Group 5A), and CH + 2% CHX + PPI 25 µg/ml (Group 5B). The groups were spectrophotometrically analyzed at 630 nm at 24 h to determine the group with the least optical density.  
Statistical Analysis: Comparison between the groups was done by the one-way analysis of variance and Kruskal–Wallis test for multiple comparisons.  
Results: The mean percentage inhibition of E. faecalis by Group 5A (CH + 2% CHX + PPI 6.25 µg/ml) was the highest compared to other groups. The lowest mean value was observed in Group 3A (CH + PPI 6.25 µg/ml) indicating least efficiency.  
Conclusion: There was a concentration-dependent effect of PPI on CH and CHX against E. faecalis. The maximum efficacy was found when the lower concentration of PPI was associated with CH/CHX mixture.  
Keywords: Calcium hydroxide, chlorhexidine, Enterococcus faecalis, intracanal medicaments, proton-pump inhibitors, root canal, spectrophotometry

Address for correspondence: Dr. R Anija, Department of Conservative Dentistry and Endodontics, Regional Dental College, Guwahati - 781 032, Assam, India.  
E-mail: ranija018@gmail.com  
Submitted: 17-Jul-2020, Revised: 23-Dec-2020, Accepted: 19-Jan-2021, Published: 14-May-2021

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHRLPMedknow_reprints@wolterskluwer.com

How to cite this article: Anija R, Kalita C, Bhuyan AC, Hussain MD, Saikia A, Das L. Comparative evaluation of the concentration-dependent effect of proton-pump inhibitor in association with calcium hydroxide and chlorhexidine on Enterococcus faecalis: An in vitro study. J Oral Maxillofac Pathol 2021;25:198.
**INTRODUCTION**

*Enterococci* are Gram-positive, facultative anaerobic cocci, which are resilient by nature and able to survive a wide array of hostile conditions.[1] *Enterococcus faecalis*, the predominant human *Enterococcus*, is not a normal commensal in the oral cavity; however, it can be conceived directly or indirectly based on the oral status. *E. faecalis* can be commonly retrieved from dorsum of the tongue (55%), gingival sulcus (22%) and oral rinse samples (29%).[2] It can get incorporated into the oral cavity by food contaminants and also by nosocomial infections. *E. faecalis* has also been related to various oral diseases, such as caries, endodontic infections, chronic periodontitis (41.7%)[3] and peri-implantitis. It is a persistent organism that plays a major role in the etiology of secondary periradicular lesions after the root canal treatment. Its prevalence ranges from 4% to 40% in primary endodontic infections[4] and 24% to 77% in persistent and secondary infections.[4,5] The eradication of *E. faecalis* is challenging in endodontically treated teeth because of its inherent ability to tolerate starvation, extremes of pH, salt concentration, biofilm formation, dentin tubular invasion and emergence of antibiotic resistant strains.[6,7]

Intracanal medications have a long history of use as interim appointment dressings to reduce the microbial load. Calcium hydroxide (CH) is the most common and widely used intracanal medicament. It has an initial pH of approximately 12, but these values do not commonly exceed 11 throughout the entire length of the canal, especially in the tubules, because of the dentin buffering capacity.[8,9] According to Evans *et al*.,[10] when the challenge is to survive in an alkaline medium, as in the presence of CH dressings, the main tactic of *E. faecalis* is to use an existing functional proton pump in their cell membrane that is capable of maintaining the homeostasis of the cytoplasm, even in a pH around 11.5. Proton pump inhibitors (PPIs) are used widely in the treatment of peptic ulcers of microbial origin along with antibiotics. The effect of incorporating PPIs with CH has been widely studied.

Chlorhexidine (CHX) gluconate (2%) has been recommended as a potential alternative to CH. In the past, many studies have been done regarding the efficacy of CH and CHX mixture and its antibacterial property and have emphasized the concept that their antimicrobial properties interact in a synergistic fashion which enhances their efficacy.[11] The tissue reactions to the mixture of CH/CHX have also been studied, and it is found that the combination exerts good antimicrobial properties and improves healing of the periapical tissues.[12]

The majority of these studies have been carried out using culturing techniques; however, polymerase chain reaction is currently a more accurate method for the detection of *E. faecalis*.[13] An optical spectroscopy-based chairside method has also been studied to rapidly monitor the presence or absence of *E. faecalis* in the root canal system.[14]

The aim of this study was to evaluate the efficacy of the association of different concentrations of PPI (Lansoprazole) with CH and CHX against *E. faecalis* using a broth dilution method. The null hypothesis states that there is no concentration-dependent effect of the PPI lansoprazole in association with CH and CHX on the inhibition of *E. faecalis*.

**MATERIALS AND METHODS**

**Preparation of the test organism**

Pure culture of *E. faecalis* (ATCC 29212) was used as the test organism and was incubated in brain–heart infusion (BHI) broth. Bacterial growth of this master broth (MB) was confirmed by the presence of turbidity. Ten milliliters of the sterilized BHI broth were inoculated with 500 µl of *E. faecalis* from the MB in test tubes and incubated at 37°C for 5 h. The growth of bacteria was confirmed by the turbidity of the broth.

**Preparation of the stock solution**

CH powder (Prevest Denpro Ltd., Jammu, India) was mixed with deionized water to attain a concentration of 16 mg/ml.[15] pH of the prepared CH was determined using a pH meter as 12.5 (Oakton Pvt. Ltd., Hyderabad, Telangana, India). PPI lansoprazole powder (Prevacid, Takeda Pharmaceuticals U. S. A.) was mixed with deionized water at a concentration of 1 mg/ml and dilutions made at 6.25 and 25 µg/ml.[16,17] CHX 2% solution (Anabond Asep-RC) was used.

**Antibacterial assessment**

Tubes were divided into five main groups. Groups 3, 4, and 5 were further subgrouped into “A” and “B” based on the concentration of lansoprazole at 6.25 µg/ml and 25 µg/ml, respectively, as listed below.

- **Group 1**: CH alone
- **Group 2**: CH + 2% CHX
- **Group 3A**: CH + Lansoprazole 6.25 µg/ml
- **Group 3B**: CH + Lansoprazole 25 µg/ml
- **Group 4A**: 2% CHX + Lansoprazole 6.25 µg/ml
- **Group 4B**: 2% CHX + Lansoprazole 25 µg/ml
- **Group 5A**: CH + 2% CHX + Lansoprazole 6.25 µg/ml
- **Group 5B**: CH + 2% CHX + Lansoprazole 25 µg/ml.

200 µL of CH, 200 µL of CH with 200 µL of CHX and 200 µL CH with lansoprazole in the two dilutions as
described were added to experimental groups yielding a total volume of 10 ml. Furthermore, reference blanks for each group were prepared. The schematic diagram of the preparation of the experimental groups is depicted in Figure 1.

Entire procedure was carried out in a biosafety hood (Class II Biohazard safety cabinet, ESCO, Singapore) maintaining sterilization and disinfection. 500 µl of *E. faecalis* was again incubated in 10 ml of sterile BHI broth to obtain MB and this served as the negative control. The MB along with the tubes (experimental groups) was incubated at 37°C for 24 h. The tubes (experimental groups, reference blanks of each groups and MB) were then evaluated for optical density (OD) at 630 nm after 24 h using ultraviolet visible Spectrophotometer (Specord 50 Plus, Analytikjena, Jena, Germany). Three readings of the experimental groups were taken corresponding to the reference blanks. Three readings of the MB were also taken to obtain its OD.

The percentage inhibition of growth was calculated as per Wang *et al.*:

\[
\text{Percentage inhibition} = \left( \frac{(\text{OD})_{\text{MB}} - (\text{OD})_{\text{Test}}}{(\text{OD})_{\text{MB}}} \right) \times 100\%
\]

Where, \((\text{OD})_{\text{MB}}\) was an average of three replicates of light absorption values at wavelength 630 nm of the control, and \((\text{OD})_{\text{Test}}\) was an average of three replicates of light absorption values at wavelength 630 nm of the experimental groups.

**Statistical analysis**

Comparison between the groups was done by the one-way analysis of variance and Kruskal–Wallis test for multiple comparisons. The level of significance (P) was set at 0.05.

**RESULTS**

The null hypothesis was rejected as there was a definite concentration-dependent effect of the PPIs on the growth inhibition of *E. faecalis* when associated with CH and CHX. The mean percentage inhibition of Group 5A (CH + 2% CHX + lansoprazole 6.25 µg/ml) is observed to be 96.03% ± 0.60% which indicates the highest efficiency compared to all other groups, followed by Group 2 (CH + 2% CHX) with a mean of 88.44% ± 0.24% and Group 4A (2% CHX + lansoprazole 6.25 µg/ml) with a mean of 80.61% ± 0.49%. The lowest mean value of 14.74% ± 0.24% is observed in Group 3A (CH + lansoprazole 6.25 µg/ml) indicating
least efficiency. Kruskal–Wallis test at 0.05 significance level shows that the difference in the values is statistically significant with $P = 0.002$ [Table 1].

The pairwise comparison of the groups is depicted in Table 2. It is observed that the significant difference in terms of mean percentage zone of inhibition exists between Group 3A and Group 5A ($P < 0.001$). Group 5A is also found to be significantly different from Group 4B ($P = 0.002$), Group 1 ($P = 0.009$) and Group 5B ($P = 0.038$). Group 3A is also found to be significantly different from Group 2 ($P = 0.002$), Group 4A ($P = 0.009$) and Group 3B ($P = 0.038$).

**DISCUSSION**

The oral cavity may serve as a reservoir for the bacterial pathogens of medical importance such as *Enterococci* in systemically healthy or diseased participants. Oral *E. faecalis* possess virulence factors that may contribute to the pathogenesis of apical periodontitis and failed root canal treatment. The success of the root canal treatment entirely relies on the complete elimination of microorganisms from the root canal anatomy. Intracanal medicaments by virtue of their longer contact time with the microorganisms can effectively eliminate these pathogens from the root canal system. CH is the most commonly used intracanal medicament. The antimicrobial effect of CH is due to the release of hydroxyl ions, a highly reactive oxidative species in an aqueous environment which diffuse into the dentinal tubules. Various reasons have been proposed for the resistance of *E. faecalis* with CH, out of which the most relevant seems to be the presence of a proton pump, which lowers the cytoplasmic pH by pumping protons into the cell. PPIs are commonly used in association with antibiotics to treat peptic ulcer disease of microbial origin (in the presence of *Helicobacter pylori*). These cause an irreversible inhibition of the H+/K+ ATPase in the parietal cells of the stomach leading to reduced gastric acid secretion, and thus are a drug of choice for gastric/duodenal ulcers and gastroesophageal reflux diseases. They increase the efficacy of antibiotics by decreasing the intragastric acidity. Lansoprazole represents the new generation of PPIs used extensively in medicine for gastric disorders.

**Table 1: Comparison of the mean percentage inhibition among the groups**

| Group  | $n$ | Mean percentage inhibition (%) | SD (%) | Minimum (%) | Maximum (%) | Kruskal-Wallis test, $P$ |
|--------|-----|--------------------------------|--------|-------------|-------------|--------------------------|
| Group 1| 3   | 71.39                          | 0.26   | 71.20       | 71.69       | 0.002*                   |
| Group 2| 3   | 88.44                          | 0.24   | 88.17       | 88.58       |                         |
| Group 3A | 3   | 14.74                          | 1.43   | 13.27       | 16.13       |                         |
| Group 3B | 3   | 76.58                          | 0.86   | 75.93       | 77.56       |                         |
| Group 4A | 3   | 80.61                          | 0.49   | 80.09       | 81.07       |                         |
| Group 4B | 3   | 50.86                          | 0.65   | 50.23       | 51.54       |                         |
| Group 5A | 3   | 96.03                          | 0.60   | 95          | 96          |                         |
| Group 5B | 3   | 72.94                          | 0.95   | 72.10       | 73.97       |                         |

*S: Significant. SD: Standard deviation

**Table 2: Kruskal-Wallis pairwise comparisons of the groups with statistically significant differences in mean percent zone of inhibition at 0.05 significance level**

| Pairwise groups | 1   | 2   | 3A  | 3B  | 4A  | 4B  | 5A  |
|-----------------|-----|-----|-----|-----|-----|-----|-----|
| 2   |     | 0.038, S |     |     |     |     |     |
| 3A  | 0.299, NS |     | 0.002, S |     |     |     |     |
| 3B  | 0.299, NS | 0.299, NS | 0.038, S |     |     |     |     |
| 4A  | 0.119, NS | 0.603, NS | 0.603, NS | 0.603, NS |     |     |     |
| 4B  | 0.603, NS | 0.009, S | 0.603, NS | 0.603, NS | 0.119, NS | 0.038, S |     |
| 5A  | 0.009, S | 0.603, NS | P < 0.001, S | 0.119, NS | 0.299, NS | 0.002, S |     |
| 5B  | 0.603, NS | 0.119, NS | 0.119, NS | 0.603, NS | 0.299, NS | 0.299, NS | 0.038, S |

S: Significant, NS: Nonsignificant
In dental literature, Wagner et al.\(^{[27]}\) were the first to attempt eradication of *E. faecalis* using CH supplemented with PPI omeprazole, who used a rat model of periapical lesion and compared it to conventional CH intracanal dressing. They obtained superior healing rates with CH supplemented with omeprazole than conventional CH dressing. Ganesh et al.\(^{[16]}\) reported concentration dependent effect of PPI (lansoprazole) with CH against *E. faecalis*. Mehta et al.\(^{[28]}\) reported that PPI enhanced the antibacterial efficacy of CH against *E. faecalis* using microdilution assay; however, variation in the concentration of omeprazole did not affect the result. Kar et al.\(^{[29]}\) also reported that the antimicrobial efficacy of omeprazole (PPI) combined with CH showed the maximum zone of inhibition against *E. faecalis*. The studies that contradicts the result of this study are by Mitthra et al.\(^{[30]}\) and Suresh et al.\(^{[31]}\) who demonstrated an *in vitro* agar diffusion assay that showed that the addition of PPI (Pantoprazole) to CH did not enhance the antimicrobial efficacy of CH when compared to CHX. The variation in results may be due to the difference in the tested drugs and methodology used.

The qualitative and quantitative applications of absorption spectrometry make use of the Beer-Lambert’s law and display characteristic absorption spectrum for molecular identification.\(^{[32]}\) The optical spectroscopic analysis of *E. faecalis* suspension have shown a conspicuous increase in absorbance intensity at spectral range from 600 to 654 nm,\(^{[14]}\) and hence, 630 nm is chosen to determine the OD in this broth dilution study.

In the present study, the maximum *E. faecalis* growth inhibition was shown by Group 5A (CH + 2% CHX + lansoprazole 6.25 µg/ml), followed by Group 2 (CH + 2% CHX) and Group 4A (2% CHX + lansoprazole 6.25 µg/ml). The least inhibition was observed in Group 3A (CH + lansoprazole 6.25 µg/ml). The expected mechanism of action favoring enhanced action in Group 5A is PPI blocks the proton pump in the cell wall of *E. faecalis*. This blocking makes the CH and CHX readily available for action directly over the organism, thereby resulting in enhanced elimination of *E. faecalis*. The groups containing lansoprazole at a concentration of 6.25 µg/ml (Group 4A and 5A) have exhibited extremely good results when associated with CHX. This better result can be attributed to the property of CHX. However, when associated with CH alone, high concentration of lansoprazole (25 µg/ml) seems to be effective against *E. faecalis*.

The exact mechanism of concentration-dependent effect of PPIs on CH/CHX mixture is not clearly understood. Further studies are needed to evaluate the chemical interaction between lansoprazole, CH and CHX and its antibacterial efficacy against *E. faecalis* at various concentrations and also *in vivo* conditions.

**CONCLUSION**

Within the limitations of this *in vitro* study, it can be concluded that there was a concentration dependent effect of PPI (Lansoprazole) on CH and CHX against *E. faecalis*. The maximum efficacy was found when the lower concentration of PPI was associated with CH/CHX mixture.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Van Tyne D, Gilmore MS. Friend turned foe: Evolution of enterococcal virulence and antibiotic resistance. Annu Rev Microbiol 2014;68:337-56.
2. Sedgley C, Buck G, Appelbe O. Prevalence of *Enterococcus faecalis* at multiple oral sites in endodontic patients using culture and PCR. J Endod 2006;32:104-9.
3. Chidambark CK, Shankar SM, Raghu P, Gururaj SB, Bushan KS. Detection of *Enterococcus faecalis* in subgingival biofilms of healthy, gingivitis, and chronic periodontitis subjects. J Indian Soc Periodontol 2019;23:416-8.
4. Rôças IN, Siqueira JF Jr., Santos KR. Association of *Enterococcus faecalis* with different forms of periodical diseases. J Endod 2004;30:315-20.
5. Molander A, Reit C, Dahlén G, Kvist T. Microbiological status of root-filled teeth with apical periodontitis. Int Endod J 1998;31:1-7.
6. Gilmore MS, Clewell DB, Courvalin P, Dunny GM, Murray BE, Rice LB, et al. The Enterococci: Pathogenesis, Molecular Biology, and Antibiotic Resistance. Vol. 10. Washington, DC: ASM Press; 2002.
7. Tendolkar PM, Baghdary AN, Shankar N. Pathogenic enterococci: New developments in the 21st century. Cell Mol Life Sci 2003;60:2622-36.
8. Haapasalo HK, Sireen EK, Waltimo TM, Orstavik D, Haapasalo MP. Inactivation of local root canal medicaments by dentine: An *in vitro* study. Int Endod J 2000;33:126-31.
9. McHugh CP, Zhang P, Michalek S, Eleazer PD. pH required to kill *Enterococcus faecalis* in vivo. J Endod 2004;30:218-9.
10. Evans M, Davies JK, Sundqvist G, Figdor D. Mechanisms involved in the resistance of *Enterococcus faecalis* to calcium hydroxide. Int Endod J 2002;35:221-8.
11. Basrani B, Ghanem A, Tjaderhane L. Physical and chemical properties of chlorhexidine and calcium hydroxide-containing medications. J Endod 2004;30:413-7.
12. Soares JA, Leonardo MR, da Silva LA, Tanomaru Filho M, Ito IY. Effect of rotary instrumentation and of the association of calcium hydroxide and chlorhexidine on the antisepsis of the root canal system in dogs. Braz Oral Res 2006;20:120-6.
13. Molander A, Lundquist P, Papapanou PN, Dahlén G, Reit C. A protocol for polymerase chain reaction detection of *Enterococcus faecalis* and *Enterococcus fæcium* from the root canal. Int Endod J 2002;35:1-6.
14. Kishen A, Chen NN, Tan L, Asundi A. Chairside sensor for rapid monitoring of *Enterococcus faecalis* activity. J Endod 2004;30:672-5.
15. Dean J, editor. Lange’s Handbook of Chemistry. 12th ed., New York, NY: McGraw-Hill; 1978. p. 1470. J Pharm Sci 1979;68:805-6.
16. Ganesh C, Koshy PA, Devi LS, Sreedhar S, Aravind L, Nair S, et al. Comparative evaluation of the effect of proton pump inhibitors associated with calcium hydroxide on Enterococcus faecalis. An in vitro study. Endodontology 2016;28(7).

17. Ni W, Cai X, Liang B, Cai Y, Cai J, Wang R. Effect of proton pump inhibitors on in vitro activity of tigecycline against several common clinical pathogens. PLoS One 2014;9(8):e86715.

18. Available from: https://msu.edu/course/lbs/159h/Spectrophotometry04.pdf. [Last assessed on 17 Feb 2021].

19. Wang J, Liu H, Zhao J, Gao H, Zhou I, Liu Z, et al. Antimicrobial and antioxidant activities of the root bark essential oil of Periploca sepium and its main component 2-hydroxy-4-methoxybenzaldehyde. Molecules 2010;15:5807-17.

20. Freeman BA, Crapo JD. Biology of disease: Free radicals and tissue injury. Lab Invest 1982;47:412-26.

21. Wang JD, Hume WR. Diffusion of hydrogen ion and hydroxyl ion from various sources through dentine. Int Endod J 1988;21:17-26.

22. Delgado RJ, Gasparoto TH, Sipert CR, Pinheiro CR, Moraes IG, Garcia RB, et al. Antimicrobial effects of calcium hydroxide and chlorhexidine on Enterococcus faecalis. J Endod 2010;36:1389-93.

23. Athanassiadis B, Abbott P, Walsh J. The use of calcium hydroxide, antibiotics and bioactives as antimicrobial medicaments in endodontics. Aust Dent J 2007;52:564-82.

24. Evans MD, Baumgartner JC, Khemaleelakul SU, Xia T. Efficacy of calcium hydroxide and chlorhexidine as an intracanal medication in bovine dentin. J Endod 2003;29:338-9.

25. Podbielski A, Spahr A, Haller B. Additive antimicrobial activity of calcium hydroxide and chlorhexidine on common endodontic bacterial pathogens. J Endod 2003;29:340-5.

26. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003;2:132-9.

27. Wagner C, Barth VC Jr., de Oliveira SD, Campos MM. Effectiveness of the proton pump inhibitor omeprazole associated with calcium hydroxide as intracanal medication: An in vivo study. J Endod 2011;37:1253-7.

28. Mehta S, Verma P, Tikku AP, Chandra A, Bains R, Banerjee G. Comparative evaluation of antimicrobial efficacy of triple antibiotic paste, calcium hydroxide, and a proton pump inhibitor against resistant root canal pathogens. Eur J Dent 2017;11:053-7.

29. Kar S, Bera S, Karmakar D. Comparative evaluation of the antibacterial efficacy of calcium hydroxide as an intracanal medicament and combination of calcium hydroxide with food preservatives and proton pump inhibitor against Enterococcus faecalis – An in vitro study. Paripex Indian J Res 2020;9:1-3.

30. Subbiya A, Vivekanandhan P, Mithra S, Abraham TA, Padmavathy K, Mahalakshmi K, et al. Antibacterial efficacy of Nisin and calcium hydroxide with a proton pump inhibitor as an intracanal medicament. World J Dent 2018;9:111-6.

31. Suresh M, Abraham TA, Padmavathy K, Mahalakshmi K, Venkatesh A, Vivekanandhan P, et al. Pantoprazole - does it enhance the antibacterial efficacy of calcium hydroxide against Enterococcus faecalis. Int J Pharm Bio Sci 2015;6:734-9.

32. Ball D. The Basics of Spectroscopy. Bellingham, WA: SPIE- The International Society for Optical Engineering: 2001.